Shares of AbbVie Inc. ABBV rallied 1.37% to $173.70 Thursday, on what proved to be an all-around rough trading session for ...

By Sneha S K and Christy Santhosh (Reuters) -AbbVie plans to "commit less capital" towards experimental medicines for ...

Leerink Partners analyst David Risinger has reiterated their bullish stance on ABBV stock, giving a Buy rating yesterday.Stay Ahead of the ...

AbbVie will commit "less capital" towards experimental medicines for psychiatric disease, CEO Robert Michael said at an ...

The schizophrenia drug Emraclidine failed to perform in clinical trials but executives say it can still “play a role.” ...

Abbvie said on Friday it would record a charge of about $3.5 billion related to its experimental schizophrenia drug, ...

Emraclidine was the centerpiece of AbbVie’s $8.7 billion acquisition of Cerevel in December 2023 but failed two mid-stage ...

Even after a flurry of corporate updates during the first two days of the J.P. Morgan Healthcare Conference, many more ...

AbbVie Inc. closed $31.77 below its 52-week high ($207.32), which the company reached on October 31st.

Even before that deal, AbbVie had been showing an interest in the modality, with then-CEO Richard Gonzalez telling analysts ...

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with ...

The company's immunology portfolio, led by Skyrizi and Rinvoq, continues to thrive despite Humira's patent expiration, ...